Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4U.S. Government Printing Office, 1994 - 198 pages |
From inside the book
Results 1-5 of 40
Page 3
... less onerous in terms of the effect on quality of life . So I see great opportunities for health care in biotechnology . At the same time , I also see concerns , and the concern that I see is that as we get more proficient technically ...
... less onerous in terms of the effect on quality of life . So I see great opportunities for health care in biotechnology . At the same time , I also see concerns , and the concern that I see is that as we get more proficient technically ...
Page 4
... less than three months ago , we hear nearly unanimous testimony that biotechnology companies are co cerned about President Clinton's Health Security Act as it is cu rently written . The provisions setting price controls on break through ...
... less than three months ago , we hear nearly unanimous testimony that biotechnology companies are co cerned about President Clinton's Health Security Act as it is cu rently written . The provisions setting price controls on break through ...
Page 8
... less than two years in cash raise cash through venture capital , public offerings , which th 1993 were largely closed to them . So that was the pictu months ago . It has frankly grown increasingly desperate . At first there was just a ...
... less than two years in cash raise cash through venture capital , public offerings , which th 1993 were largely closed to them . So that was the pictu months ago . It has frankly grown increasingly desperate . At first there was just a ...
Page 14
... Less , Get More , " Business Week , June 28 , 1993 . ' G. Steven Burrill and Kenneth B. Lee , Jr. , Biotech 94 Long Term Value Short Term Hurdles , Eighth Annual Report on the Biotech Industry , pg . VIII . Top 10 Companies - R & D ...
... Less , Get More , " Business Week , June 28 , 1993 . ' G. Steven Burrill and Kenneth B. Lee , Jr. , Biotech 94 Long Term Value Short Term Hurdles , Eighth Annual Report on the Biotech Industry , pg . VIII . Top 10 Companies - R & D ...
Page 17
... less than 1 % are profitable . This is an industry that cannot borrow any money from banks . It is an industry that depends on equity capital markets and is extremely vulnerable . The funds for research do not come from the government ...
... less than 1 % are profitable . This is an industry that cannot borrow any money from banks . It is an industry that depends on equity capital markets and is extremely vulnerable . The funds for research do not come from the government ...
Other editions - View all
Common terms and phrases
administration Administration's American antibody biotech biotech companies biotech firms biotechnology companies biotechnology industry Biotechnology Industry Organization bone marrow transplant breakthrough drugs breast cancer CANCE cancer cells cancer patients cancer research capital Chairman chemotherapy clinical trials Clinton colon cancer colorectal cancer committee competition Congress Curd cure disease doctors drug companies drug costs drug prices Duke effective Federal FELDBAUM funding gastrointestinal gene therapy Genentech global going health care costs health care reform health care system HOKE hospital human impact incidence increased innovation investment investors Japan Johnson KLEIN manufacturing medicine million National Cancer Institute percent pharmaceutical industry prescription President price controls Price Regulation profits proposed protein receptor regulatory research and development result spending subcommittee surgery Thank therapeutic Tim Valentine treat TREATMENT OF COLORECTAL tumor United VALENTINE WAGNER-JOHNSON women
Popular passages
Page 75 - Never doubt that a small group of thoughtful committed citizens can change the world. Indeed it's the only thing that ever has.
Page 140 - The purpose of the Agency is to enhance the quality, appropriateness, and effectiveness of health care services, and access to such services, through the establishment of a broad base of scientific research and through the promotion of improvements in clinical practice (including the prevention of diseases and other health conditions) and in the organization, financing, and delivery of health care services.
Page 179 - R&D as a percent of sales for seven major drug companies is compared to Federal health care research spending as a percent of health care costs. This graph shows that major drug companies have doubled their...
Page 128 - Kaposi's sarcoma (KS) was examined with the use of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Page 52 - Reforms Needed in the Organization, Management, and Resources of the Food and Drug Administration's Center for Devices and Radiological Health.
Page 179 - One of out of every three living Americans will die of cancer. Currently, there are over 8 million cancer patients in the US You can think of them as having tested positive for cancer. I talk with hundreds of cancer patients every year. I get phone calls every day and I know their problems with the health care system. First, and foremost, they haven't got a cure for their disease.
Page 182 - Lower market value* mean that the cost of capital is going up and less capital is available. ultimately, capital flows are reflected in research budgets as well as in prices . As I mentioned, I have been involved in several high tech ventures. Currently* "word on the street...
Page 4 - I thank all of you for being here, and I look forward to hearing your testimony. Thank you, Mr. Chairman.
Page 67 - I would be pleased to answer any questions you might have. Thank you. [The prepared statement of Mr.
Page 2 - Thank you very much, Mr. Chairman. I first want to express my...